<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Contraception: Postpartum counseling and methods
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Contraception: Postpartum counseling and methods
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Contraception: Postpartum counseling and methods
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sarita Sonalkar, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheila K Mody, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Courtney A Schreiber, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen Eckler, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 24, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1718239255">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The postpartum period is an ideal time to access contraception services, as patients are known to not be pregnant, they may be motivated to initiate contraception, and are under the care of clinicians with the appropriate expertise. Counseling involves understanding a patient's wishes regarding future pregnancy, their preferences regarding contraceptive options, and the characteristics and attributes of the contraceptive methods themselves. Additional medical considerations include timing of contraceptive start after delivery, medical comorbidities, and breastfeeding status.
        </p>
        <p>
         This topic will review the available data and guidelines surrounding counseling patients about contraceptive selection and initiation in the postpartum period. Related information on contraceptive counseling and selection in general is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">
          "Contraception: Counseling and selection"
         </a>
         .)
        </p>
        <p>
         In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. We encourage the reader to consider the specific counseling and treatment needs of transgender and gender-expansive individuals.
        </p>
        <p class="headingAnchor" id="H3421958576">
         <span class="h1">
          RESUMPTION OF OVULATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a systematic review of studies estimating the time to return to fertility in nonlactating postpartum people, the average time to first ovulation varied from 45 to 94 days postpartum, with the earliest reported ovulations at 25 and 27 days postpartum [
         <a href="#rid1">
          1
         </a>
         ]. Although many first ovulations will be subfertile, some of the reported ovulations were estimated to be fertile, which highlights the importance of timely initiation of contraception postpartum. To address contraception and other acute postpartum needs in a timely way, postpartum follow-up within two to three weeks is advised [
         <a href="#rid2">
          2
         </a>
         ]. Studies have documented wide variation in the percentage of people who attend the six-week postpartum visit (65 to 90 percent) [
         <a href="#rid3">
          3
         </a>
         ]. In addition, a significant proportion of people, up to 51 percent in one study, will resume sexual activity before the six-week postpartum visit [
         <a href="#rid1">
          1,4,5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H82582547">
         <span class="h1">
          INTERPREGNANCY INTERVAL AND ROLE OF CONTRACEPTION ACCESS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on studies reporting adverse maternal, perinatal, and infant outcomes with shorter interpregnancy intervals (IPI; the interval between a live birth and conception of another pregnancy), the World Health Organization advises an interval of at least 24 months [
         <a href="#rid6">
          6-9
         </a>
         ]. Similarly, the American College of Obstetricians and Gynecologists advises that patients should be counseled to avoid IPIs shorter than six months and be counseled about the risks and benefits of repeat pregnancy sooner than 18 months [
         <a href="#rid2">
          2
         </a>
         ]. Adverse outcomes with short IPIs have been reported in both low- and high-resource settings, although data from studies in higher resource settings reported weaker associations between adverse outcomes and IPIs greater than six months as compared with intervals less than six months [
         <a href="#rid7">
          7
         </a>
         ]. Despite these recommendations, international estimates of the unmet need for postpartum contraception are as high as 62 percent in the first year following childbirth [
         <a href="#rid10">
          10-12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6767.html" rel="external">
          "Interpregnancy interval: Optimizing time between pregnancies"
         </a>
         .)
        </p>
        <p>
         From a public health perspective, IPI is clearly associated with the effectiveness of the postpartum contraceptive method; patients who use less effective methods are more likely to have shorter IPIs [
         <a href="#rid13">
          13-15
         </a>
         ]. Conversely, initiation of one of the most effective contraceptives after delivery, including permanent contraception and long-acting reversible contraception (LARC), is associated with an 80 percent lower hazard of having a repeat delivery within 27 months compared with patients who did not initiate contraception [
         <a href="#rid13">
          13
         </a>
         ]. Further, health policies that mandate insurance coverage of postpartum LARC are associated with increased rates of LARC usage [
         <a href="#rid16">
          16
         </a>
         ] and a subsequent decrease in short-interval births among adult and adolescent patients [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
         However, intent alone is ineffective if the contraceptive method is not available to the patient because of issues related to cost, staff education and training, or logistics. For example, patients who are unable to receive a desired postpartum permanent contraception during their birth hospitalization are at higher risk of pregnancy within one year compared with patients who do not request postpartum permanent contraception at all [
         <a href="#rid19">
          19
         </a>
         ]. Internationally, the lactational amenorrhea method of contraception is often emphasized given its high initial efficacy and low risk [
         <a href="#rid20">
          20
         </a>
         ] (see
         <a class="local">
          'Other'
         </a>
         below). However, this method is temporary, and patients may not visit a care provider during a time when a transition to another method is indicated. Thus, we advise that clinicians prioritize educating patients about birth spacing and patient-appropriate postpartum contraceptive options, ensuring method access prior to discharge, and arranging timely postpartum follow-up.
        </p>
        <p class="headingAnchor" id="H1562672056">
         <span class="h1">
          OUR APPROACH TO COUNSELING
         </span>
         <span class="headingEndMark">
          —
         </span>
         For counseling patients about contraception, we use a patient-centered, shared decision-making model. Shared decision making is "a collaborative process that allows patients and their clinicians to make health care decisions together, taking into account the best scientific evidence available, as well as the patient's values and preferences… this process provides patients with the support they need to make the best individualized care decisions" [
         <a href="#rid21">
          21
         </a>
         ]. Decisions about birth spacing are informed by multiple factors, including desired family size, beliefs about and access to contraception, and maternal age. Furthermore, the postpartum period is a clinically dynamic time, in which method eligibility may change based on venous thromboembolism (VTE) risk, breastfeeding status, and medical comorbidities. Patients often have a clear plan for postpartum contraception if counseling is done during the prenatal period, which then allows clinicians to ensure the desired method is available after delivery. Helping clinicians comprehensively, meaningfully, and accurately counsel postpartum patients regarding family planning is an important step in decreasing unmet need for postpartum family planning. Keeping system factors in mind during counseling is also important. For example, some patients may be insured for a limited time after delivery, and certain hospital systems may restrict access to contraceptive methods due to religious restrictions [
         <a href="#rid22">
          22
         </a>
         ]. As patients do not necessarily fully understand system barriers, clinicians may need to advocate on their behalf and bridge gaps for patients who desire access to postpartum contraception [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p>
         We take the following approach, ideally starting during prenatal care, with portions repeated as needed  (
         <a class="graphic graphic_algorithm graphicRef119286" href="/z/d/graphic/119286.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Discuss their reproductive life plan
         </strong>
         – Eliciting a discussion of a person's reproductive life plan is a natural start to counseling regarding postpartum contraception. This conversation should include questions about desire for, and timing of, any future pregnancies and should begin during prenatal care. We start a discussion about postpartum contraception broadly by first asking patients what their ideal family size might be. More specifically, clinicians can ask, "After you deliver, are you interested in having more children?" If they would like to have additional children, a follow-up question can be, "When do you think that might be?" [
         <a href="#rid24">
          24
         </a>
         ]. This moment in the conversation may be appropriate for discussing health benefits of birth spacing, taking into account individual circumstances such as desired family size, personal values about birth spacing, and maternal age to guide creation of a reproductive health plan that is based on patient values as well as evidence-based recommendations  (
         <a class="graphic graphic_table graphicRef120109" href="/z/d/graphic/120109.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid6">
          6-9,25
         </a>
         ]. This can then lead to a discussion about whether a patient would like to actively prevent pregnancy after delivery. (See
         <a class="medical medical_review" href="/z/d/html/6767.html" rel="external">
          "Interpregnancy interval: Optimizing time between pregnancies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The choice of contraception is ultimately made by the patient. Detailed discussions of contraceptive efficacy and the general approach to method selection are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">
          "Contraception: Counseling and selection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Discuss contraceptive characteristics
         </strong>
         – Once the patient's desire for additional children and subsequent birth spacing has been established, we determine the contraceptive characteristics that she values most at that time. We ask, "What is most important to you in a contraceptive method?" [
         <a href="#rid21">
          21
         </a>
         ]. Attributes that patients may value in contraceptive methods include efficacy  (
         <a class="graphic graphic_figure graphicRef119765" href="/z/d/graphic/119765.html" rel="external">
          figure 1
         </a>
         ), convenience (both in obtaining and using the method), cost, the ability to control whether to use the method, effect on uterine bleeding [
         <a href="#rid26">
          26
         </a>
         ], and compatibility with breastfeeding. The ensuing conversation then starts with a discussion of the methods with the patient's most valued characteristic(s). For example, if a patient does not desire more children and values efficacy, then highly effective methods (ie, permanent or long-acting) would be discussed first and in detail. Even for patients with a clear contraceptive preference, all methods should be mentioned at least briefly to ensure the patient is fully aware of their options.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Review medical issues or comorbidities
         </strong>
         – In the first six weeks postpartum, multiple dynamic medical factors inform contraceptive method selection, particularly the elevated risk of VTE. With the exception of estrogen-containing methods, the Centers for Disease Control and Prevention (CDC) US Medical Eligibility Criteria (MEC)
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=jEVGVo6WqsDq698K1C6vDPPjIqTfzg54vW4qWS3doblDMO%2BX3NN%2Fro6R0xwK%2FI6IOwBh6DyNhV%2Fq6vrv3T8nCaRCrZsEC%2BWz9FPYFmXFzWEhd9uzeVTKQGeWKf6mT23Z1X5qsRVoFq27I5l%2B8ZoObQ%3D%3D&amp;TOPIC_ID=6708" target="_blank">
          table
         </a>
         classifies all methods immediately after delivery as either a category 1 or 2 [
         <a href="#rid27">
          27,28
         </a>
         ]. The categories are defined as either no restriction (category 1) or the advantages of using the method generally outweigh the theoretical or proven risks (category 2). Due to the importance of breastfeeding in low-resource settings and the scarcity of high-quality data on the effect of hormonal contraception on breastfeeding outcomes [
         <a href="#rid29">
          29,30
         </a>
         ], the World Health Organization (WHO)
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf%3Bjsessionid%3D55C551B539A61F28BE7AE285A390FC58%3Fsequence%3D1&amp;token=prIskPfTpbcL8mRnSS6q7Hcr0tYalJMzUg36RcNANbcIemDq7OhL2c9jVDNI44wO5SbWxZcizJVzNs4c2xW37vNCZPTq4zizUxzmPhsFr8sRbLLiBIDi%2BOHm0q2FPHjjIKOEzd0EUy448DcVNjn%2Fx6d2tEQtFWHtuoephVLQgpE%3D&amp;TOPIC_ID=6708" target="_blank">
          contraceptive eligibility criteria
         </a>
         advise delaying progestin-only injectable methods to six weeks postpartum and estrogen-progestin combined methods to six months postpartum for breastfeeding patients [
         <a href="#rid28">
          28
         </a>
         ]. The WHO guidelines, which are meant to apply to a wide range of settings and resources, are interpreted below. (See
         <a class="local">
          'Impact of contraception on breastfeeding'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Discuss plans for breastfeeding
         </strong>
         – When counseling patients regarding the interaction of contraception, particularly hormonal contraception, and lactation, it is paramount to develop a collaborative model with obstetric clinicians, pediatricians, and lactation consultants, as data are sparse in this area and messaging to patients should be consistent. Furthermore, given that high-quality data are limited, it is important to avoid "bedside advocacy," in which public health messages are conveyed that primarily reflect the priorities of the clinician [
         <a href="#rid31">
          31
         </a>
         ]. Instead, we advise adopting a patient-centered, shared decision-making model, in which providers elicit patient priorities and tailor their recommendations to those priorities  (
         <a class="graphic graphic_table graphicRef120109" href="/z/d/graphic/120109.html" rel="external">
          table 1
         </a>
         ). All contraceptives are considered compatible with breastfeeding. (See
         <a class="local">
          'Impact of contraception on breastfeeding'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2725790689">
         <span class="h1">
          METHODS
         </span>
        </p>
        <p class="headingAnchor" id="H4188920417">
         <span class="h2">
          Permanent contraception
         </span>
         <span class="headingEndMark">
          —
         </span>
         Permanent contraception for either the female or male partner is an option for patients who do not desire future pregnancy. Efficacy rates are greater than 99 percent  (
         <a class="graphic graphic_figure graphicRef119765" href="/z/d/graphic/119765.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Female
         </strong>
         – Postpartum permanent contraception may be performed via bilateral partial salpingectomy or bilateral complete salpingectomy. After vaginal delivery, partial salpingectomy can be performed via infraumbilical mini-laparotomy, preferably within 24 to 48 hours but up to six days postpartum, or at the time of cesarean delivery. At cesarean delivery, bilateral complete salpingectomy (to reduce the risk of high-grade serous ovarian cancer) or partial salpingectomy can be performed. However, studies report that one-third to one-half of patients who desire postpartum permanent contraception do not receive their desired procedure; risk factors for unfulfilled permanent contraception include elevated body mass index, time of delivery, and vaginal rather than cesarean delivery [
         <a href="#rid19">
          19,32,33
         </a>
         ]. Deferral of desired permanent contraception after this time period results in high rates of unwanted pregnancy, up to 47 percent, within the first postpartum year, which is an issue for patients who deliver at hospitals with restrictive contraception policies [
         <a href="#rid19">
          19,34,35
         </a>
         ]. For patients whose desired permanent contraception is unable to be performed during the birth admission, we offer other highly effective contraceptive methods and schedule the patient for subsequent interval laparoscopic permanent contraception. (See
         <a class="medical medical_review" href="/z/d/html/101866.html" rel="external">
          "Postpartum permanent contraception: Procedures"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Counseling regarding postpartum female permanent contraception should ideally begin during the antenatal period. Shared decision making and patient-centered counseling is particularly important in preparation for permanent contraception; nonconsensual permanent contraception has been documented in the United States and other countries and has involved patients who are intellectually disabled, insured through federal funding, incarcerated, members of underrepresented groups, with chronic disease, or disenfranchised in some way [
         <a href="#rid36">
          36-40
         </a>
         ]. Cases in the United States resulted in court-mandated waiting periods for permanent contraception in patients with public insurance, although these restrictions have since been criticized for creating unnecessary barriers to permanent contraception access for this population [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Given these restrictions, a discussion about permanent contraception should not be deferred to the end of pregnancy. Consent for permanent contraception should be considered as a process of delivering information, confirming voluntariness, and confirming understanding of information and, as such, should be delivered in comprehensible language with the use of an interpreter if needed [
         <a href="#rid42">
          42
         </a>
         ]. A patient's decision regarding whether to proceed with permanent contraception should be reaffirmed during the delivery admission prior to surgery, as their wishes may have changed during their pregnancy. (See
         <a class="medical medical_review" href="/z/d/html/101560.html" rel="external">
          "Overview of female permanent contraception", section on 'Counseling'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         General information on female permanent contraception, United States mandated waiting periods, and techniques of postpartum permanent contraception are reviewed elsewhere.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/101560.html" rel="external">
          "Overview of female permanent contraception"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/101560.html" rel="external">
          "Overview of female permanent contraception", section on 'United States regulatory issues'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/101866.html" rel="external">
          "Postpartum permanent contraception: Procedures"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Male
         </strong>
         – Vasectomy is a surgical procedure that provides permanent contraception for males. Advantages include that it is highly effective (less than 1 percent failure rate), a minimally invasive outpatient procedure, and widely available. Vasectomy is presented in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/8094.html" rel="external">
          "Vasectomy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H797570952">
         <span class="h2">
          Progestin-only implants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Etonogestrel (commercial name Nexplanon) and
         <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">
          levonorgestrel
         </a>
         (LNG) implants (commercial names Jadelle and Sino-implant [II]) can be safely inserted at any time after delivery, as the advantages generally outweigh the theoretical or proven risks [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p>
         Details regarding the contraceptive implant in general, placement, and the effect of the implant on lactation are described separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant", section on 'Insertion procedure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2022126437">
         <span class="h2">
          Intrauterine devices
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both copper and LNG-releasing intrauterine devices (IUDs) can be inserted after delivery.
        </p>
        <p class="headingAnchor" id="H1831943599">
         <span class="h3">
          Device types and candidates
         </span>
         <span class="headingEndMark">
          —
         </span>
         IUD device types, candidates and device selection, techniques for placement and removal, and management of side effects and complications are described separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">
          "Intrauterine contraception: Background and device types"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5419.html" rel="external">
          "Intrauterine contraception: Candidates and device selection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3267.html" rel="external">
          "Intrauterine contraception: Insertion and removal"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5422.html" rel="external">
          "Intrauterine contraception: Management of side effects and complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2627493438">
         <span class="h3">
          Options for timing of placementafter delivery
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who desire an IUD after delivery, explicit counseling should center on timing of IUD placement. Although some outcome variables differ by timing of placement, overall, IUD insertion at all time points after delivery is safe [
         <a href="#rid43">
          43-45
         </a>
         ], with very low incidence of perforation [
         <a href="#rid46">
          46
         </a>
         ], infection [
         <a href="#rid47">
          47-50
         </a>
         ], and/or heavy vaginal bleeding [
         <a href="#rid51">
          51,52
         </a>
         ]. However, postplacental IUD placement is contraindicated in patients with chorioamnionitis, endometritis, or active postpartum hemorrhage [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3090407907">
         <span class="h3">
          Facilitating postpartum IUD placement
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Standardized counseling script embedded in the electronic health record
         </strong>
         – In our practice, we use an electronic medical record-based script to guide counseling regarding postpartum IUD placement, in which providers are prompted to review the differential risks of postplacental and delayed postpartum IUD placement including expulsion, malposition, and missing strings; that follow-up is recommended after postplacental placement to assess for positional abnormalities; and that the advantage of postplacental IUD placement is maximized for patients who may not be able to return for delayed postpartum placement or who wish to avoid a separate procedure. Although predictors for nonattendance to follow-up have been described [
         <a href="#rid53">
          53
         </a>
         ], these predictors cannot be used on an individual level to prioritize access to postplacental IUDs, particularly because follow-up after postplacental IUD placement is important in the recognition of complications of this contraceptive method.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Early postpartum evaluation
         </strong>
         – We advise removing potential barriers to a two- to three-week postpartum visit [
         <a href="#rid2">
          2,54
         </a>
         ] and early ultrasound evaluation for patients who receive a postplacental IUD, enabling sufficient time for confirmation of IUD position if needed, prior to the potential for return to fertility. Furthermore, in settings in which patients have insurance coverage for a finite number of weeks after delivery, early recognition of IUD positional abnormalities allows for clinical management during the time of coverage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Health system support for postpartum contraception
         </strong>
         – Given the public health benefit of access to immediate postpartum long-acting reversible contraceptives (LARC), health systems should work to provide this service to patients. However, logistical, financial, and educational barriers may restrict the development of these programs at a departmental level. The American College of Obstetricians and Gynecologists publishes and collates a variety of
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fprograms%2Flong-acting-reversible-contraception-larc%2Factivities-initiatives%2Fpostpartum-contraceptive-access-initiative&amp;token=eVogPyseqeYK6r1JtIGUOlTgF9t%2FC54i0ebND9MFXvwyI5dq%2F8YRAqCrBJRJrPUO6Ab2NKnihQd93bZg7vEL%2Faa5UCmL6iYr4%2B2Ebm9ogSgOZoYhgLxtGv5VwNizUHDe2fYjXDwQ9N%2F%2BpvAEjUqAaw%3D%3D&amp;TOPIC_ID=6708" target="_blank">
          resources
         </a>
         to aid in the development and sustainability of immediate postpartum LARC programs.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3726160699">
         <span class="h3">
          Issues related to postpartum IUD placement
         </span>
        </p>
        <p class="headingAnchor" id="H758103922">
         <span class="h4">
          Expulsion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Expulsion rates appear to differ by timing of IUD placement, mode of delivery, device type, and duration of follow-up studied.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing of placement
         </strong>
         – Expulsion rates vary by timing of placement and range from 10 to 40 percent for immediate and early postpartum placement to 2 to 4 percent for placement six weeks postpartum and beyond, as compared with 3 to 10 percent for non-postpartum patients [
         <a href="#rid47">
          47,55-64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a 2020 meta-analysis of 48 studies including 7661 IUD placements, immediate (less than or equal to 10 minutes after placental delivery) and early (greater than 10 minutes to less than 4 weeks postpartum) placements were associated with an eightfold increased risk of IUD expulsion compared with interval placement (adjusted risk ratio [aRR] 8.33, 95% CI 4.32-16.08) [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A prospective cohort study including over 320,000 patients given birth by either route between 2001 and 2018 reported the highest five-year cumulative IUD expulsion rates for those inserted between 0 to 3 days postpartum (10.73 percent, 95% CI 9.12-12.61) and lowest rates for IUDs inserted more than 6 but less than 14 weeks following birth (3.18 percent, 95% CI 2.95-3.42) [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a trial including patients following vaginal and cesarean birth, IUD placement two to four weeks postpartum (n = 203), compared with placement six to eight weeks postpartum (n = 201), was not associated with higher risk of complete expulsion [
         <a href="#rid65">
          65
         </a>
         ]. The predefined noninferiority margin was 6 percent (between group difference 2.0, 95% CI -0.5 to 5.7). Trial limitations included that 53 patients (13 percent) did not have an IUD placed and 57 patients (14 percent) were lost to follow-up.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaginal versus cesarean birth
         </strong>
         – Among immediate placements, vaginal birth conferred a fourfold increased risk of expulsion compared with cesarean birth (aRR 4.57; 95% CI 3.49-5.99) [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LNG versus copper IUD
         </strong>
         – Risk of expulsion at less than four weeks postpartum was nearly double for the LNG-releasing IUD compared with the copper IUD (aRR 1.91, 95% CI 1.50-2.43) [
         <a href="#rid55">
          55,62
         </a>
         ]. Among immediate postplacental placements following vaginal birth,
         <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">
          LNG IUDs
         </a>
         have nearly twice the risk of expulsion of
         <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">
          copper IUDs
         </a>
         (aRR 1.90, 95% CI 1.36-2.65).
        </p>
        <p>
        </p>
        <p>
         Using ultrasound to guide postpartum IUD placement following vaginal birth does not appear to lower IUD expulsion rates [
         <a href="#rid47">
          47,66
         </a>
         ]. In our practice, we advise patients who have had postplacental insertion of an IUD to undergo ultrasound evaluation of IUD position at four to six weeks postpartum.
        </p>
        <p class="headingAnchor" id="H2355599286">
         <span class="h4">
          Uterine perforation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Available studies suggest that the absolute risk of uterine perforation with postplacental IUD insertion is low. Some studies suggest perforation rates are no greater postpartum than with insertion more than six months following birth [
         <a href="#rid43">
          43,46,67
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Low risk of uterine perforation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A retrospective cohort study including nearly 25,000 patients receiving a postpartum IUD, absolute perforation rates were low although perforation was slightly more likely with delayed versus interval insertion (perforation after IUD insertion 4 to 8 weeks postpartum = 0.78 percent versus perforation after IUD placement 9 to 36 weeks postpartum = 0.46 percent, adjusted odds ratio 1.92, 95% ci 1.28-2.89) [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a trial of 201 participants randomly assigned to IUD placement at three or six weeks postpartum (ie, delayed postpartum insertion), no complete expulsions or perforations occurred [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Data from the Assessment of Perforation and Expulsion of Intrauterine Devices (APEX IUD) study included in the Mirena IUD labeling indicate that risks of uterine perforation are highest in those with IUD insertion less than or equal to six weeks postpartum, with higher risk in breastfeeding patients. Rate of perforation was 11 in 1000 in those who were breastfeeding and between four days and six weeks postpartum. Perforation in the early postpartum period was reported to be 4 in 1000 in breastfeeding patients and 0 in 1000 in nonbreastfeeding patients [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact of lactation
         </strong>
         – Beyond six weeks postpartum, IUD perforation rates appear to be somewhat higher in breastfeeding as compared with nonbreastfeeding participants, although overall perforation rates in both populations are exceedingly low (less than 1 percent in both groups) [
         <a href="#rid71">
          71,72
         </a>
         ]. Risk of perforation is not considered a reason to defer IUD insertion in breastfeeding patients.
        </p>
        <p>
        </p>
        <p>
         Diagnosis and management of uterine perforation are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5422.html" rel="external">
          "Intrauterine contraception: Management of side effects and complications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H122659869">
         <span class="h4">
          Abnormal IUD position
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immediate postplacental IUD placement appears to be associated with more positional abnormalities compared with delayed or interval placement.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immediate placement
         </strong>
         – A study of 200 patients receiving a copper 380 mm
         <sup>
          2
         </sup>
         IUD immediately after vaginal birth reported a 15 percent malposition rate by six months postpartum [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Delayed or interval placement
         </strong>
         – In a trial that randomized 404 postpartum patients to either early (two to four weeks) or interval (six to eight weeks) postpartum placement, the rate of malpositioned IUDs dropped to 5.4 percent following early and 0 percent with interval placement [
         <a href="#rid65">
          65
         </a>
         ].
         <sup>
         </sup>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Baseline risk
         </strong>
         – Baseline risk of malposition is extrapolated from a trial including 3755 patients (not postpartum) randomized to either LNG 52 mg or copper 380 mm
         <sup>
          2
         </sup>
         IUDs that reported "device-related" discontinuations, which included some malpositions, occurred in 0.12 to 0.24 per 1000 participants by one year [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Possible associated factors
         </strong>
         – In a case-control study, malpositioning after interval IUD placement was more likely to be identified in participants with suspected adenomyosis and less likely to be reported in participants with a prior vaginal birth and with private insurance [
         <a href="#rid74">
          74
         </a>
         ]. Physiologic reasons for these risk factors are unclear.
        </p>
        <p>
        </p>
        <p>
         However, the clinical significance of abnormal IUD position is unknown. Prior research shows that greater distance of copper from the cornua decreases effectiveness of a
         <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">
          copper IUD
         </a>
         , suggesting that IUD malposition may decrease effectiveness as well [
         <a href="#rid75">
          75,76
         </a>
         ]. The proportion of patients who experience pain or bleeding abnormalities with IUD malposition is not known [
         <a href="#rid75">
          75,76
         </a>
         ].
         <strong>
         </strong>
         Given the paucity of data in this area, we recommend offering IUD replacement to patients experiencing this outcome, especially those patients experiencing discomfort.
        </p>
        <p class="headingAnchor" id="H1493144193">
         <span class="h4">
          IUD strings
         </span>
         <span class="headingEndMark">
          —
         </span>
         IUD strings are folded into the uterus and are unable to be visualized on speculum examination in nearly one-quarter of patients who have postplacental placement after vaginal birth [
         <a href="#rid67">
          67,77
         </a>
         ]. Presence of IUD strings is a poor test to assess correct position of an IUD placed after placental delivery; conversely, absence of IUD strings is a poor test to predict abnormal IUD positioning. The sensitivity and specificity of a string check as a test for IUD position are 36.2 and 84.5 percent in patients who have a postplacental IUD after vaginal birth [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
         Patients who desire postplacental IUD insertion should be counseled regarding the potential increased risk of absent strings. In addition, patients may be bothered by long strings resulting from uterine involution after postplacental IUD placement. One study comparing postplacental with delayed
         <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">
          LNG IUD
         </a>
         insertion reported that 17 percent of patients with a postplacental IUD had an unscheduled clinic visit for IUD string trimming; unscheduled visits for string trimming were not reported for patients in the delayed insertion group [
         <a href="#rid47">
          47
         </a>
         ]. Given the lower risk of expulsion of an IUD after cesarean birth but the higher risk of nonvisible strings, string check is likely an even poorer test to assess IUD position after cesarean birth [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3363311530">
         <span class="h4">
          IUD continuation rate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite the increased risk of expulsion, perforation, and positional abnormalities after postplacental IUD insertion, the odds of using an IUD six months after delivery is twice as high for patients who receive a postplacental IUD as compared with interval insertion (odds ratio 2.04, 95% CI 1.01-4.09) [
         <a href="#rid3">
          3
         </a>
         ]. A different study reported 81 percent of patients who received a postplacental
         <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">
          copper IUD
         </a>
         were still using it six months after delivery despite the complications [
         <a href="#rid67">
          67
         </a>
         ]. This relatively high retention rate appears to translate into higher contraceptive efficacy of intended postplacental IUD placement compared with intended delayed postpartum IUD placement, as indicated by a decision analysis study [
         <a href="#rid3">
          3
         </a>
         ]. Despite higher rates of expulsion, intended postplacental IUD insertion is more effective in preventing pregnancy at one year than intended delayed insertion.
        </p>
        <p>
         The primary factor influencing variation in estimates of intended IUD effectiveness is the proportion of patients who return for a postpartum visit. A practice would need to have postpartum follow-up rates of 90 percent or greater in order for intended delayed postpartum IUD insertion to be a more effective method of contraception than intended postplacental IUD placement. On the other hand, once the IUD is placed, a delayed postpartum IUD is more effective than a postplacental IUD, due to the lower expulsion rate. Thus, public health and individual-level benefits of postplacental IUD placement may be in conflict, and it is essential to clearly educate patients on the risks and benefits of both timings of IUD placement [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2284998647">
         <span class="h2">
          Short-acting hormonal contraception
         </span>
         <span class="headingEndMark">
          —
         </span>
         Short-acting reversible hormonal contraception includes progestin injections and oral pills as well as combined estrogen-progestin products (oral pills, patch, vaginal ring). These are considered highly effective methods of contraception  (
         <a class="graphic graphic_figure graphicRef119765" href="/z/d/graphic/119765.html" rel="external">
          figure 1
         </a>
         ). While progestin-only methods can be started any time in the postpartum period, combined hormonal contraception (CHC) should not be initiated earlier than 21 days postpartum for any patient because of the increased risk of venous thromboembolism (VTE) [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Advantages of these methods include relative ease of use, wide access, relatively low upfront cost, and noncontraceptive benefits. As discussed in detail below, the World Health Organization's (WHO)
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf%3Bjsessionid%3D55C551B539A61F28BE7AE285A390FC58%3Fsequence%3D1&amp;token=prIskPfTpbcL8mRnSS6q7Hcr0tYalJMzUg36RcNANbcIemDq7OhL2c9jVDNI44wO5SbWxZcizJVzNs4c2xW37vNCZPTq4zizUxzmPhsFr8sRbLLiBIDi%2BOHm0q2FPHjjIKOEzd0EUy448DcVNjn%2Fx6d2tEQtFWHtuoephVLQgpE%3D&amp;TOPIC_ID=6708" target="_blank">
          contraceptive eligibility criteria
         </a>
         advise waiting longer before starting hormonal contraceptives in lactating patients compared with the Centers for Disease Control and Prevention (CDC)
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=jEVGVo6WqsDq698K1C6vDPPjIqTfzg54vW4qWS3doblDMO%2BX3NN%2Fro6R0xwK%2FI6IOwBh6DyNhV%2Fq6vrv3T8nCaRCrZsEC%2BWz9FPYFmXFzWEhd9uzeVTKQGeWKf6mT23Z1X5qsRVoFq27I5l%2B8ZoObQ%3D%3D&amp;TOPIC_ID=6708" target="_blank">
          table
         </a>
         . In our practice, we counsel patients that the advantages of immediate initiation of progestin-only methods are believed to outweigh the theoretical risks. We delay initiation of CHC for at least 21 days postpartum for all patients because of the increased risk of VTE. (See
         <a class="local">
          'Impact of contraception on breastfeeding'
         </a>
         below and
         <a class="local">
          'Counseling regarding venous thromboembolism risk and hormonal contraception in the postpartum period'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Progestin-only injectable
         </strong>
         – This method, which can be administered during the birth admission, has the advantage of being a single injection that lasts 12 weeks. Postpartum depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         (DMPA) can therefore bridge to an outpatient postpartum visit, at which time a patient may switch methods or continue DMPA, as desired. DMPA is available in both intramuscular and subcutaneous forms (patients may self-inject subcutaneous DMPA). Some clinicians and practitioners have raised concerns about a link between DMPA and postpartum depression, but studies have reported conflicting results. A clear link between DMPA and postpartum depression has not been proven or excluded [
         <a href="#rid79">
          79,80
         </a>
         ]. While immediate use of DMPA has been associated with a small increased risk of VTE, the overall incidence remains low [
         <a href="#rid81">
          81
         </a>
         ]. (See
         <a class="local">
          'Counseling regarding venous thromboembolism risk and hormonal contraception in the postpartum period'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patient selection, risks and benefits, and administration of
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          DMPA
         </a>
         are presented in separate discussions.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5468.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/118540.html" rel="external">
          "Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Progestin-only pills
         </strong>
         – Progestin-only pills (POPs) can be initiated at any time after delivery. Two POPs are available:
         <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">
          norethindrone
         </a>
         0.35 mg, taken at the same dose daily; and
         <a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">
          drospirenone
         </a>
         4mg, taken in a 24-4 regimen (24 active pills followed by 4 placebo pills). The efficacy of norethindrone is likely lower than CHCs due to the need to take them at nearly the same time every day [
         <a href="#rid82">
          82
         </a>
         ]. However, drospirenone, a newer POP, reliably inhibits ovulation, even in the setting of skipped pills.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a retrospective cohort study, patients who had a short interpregnancy interval were most likely (fivefold increased risk) to have been prescribed a
         <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">
          norethindrone
         </a>
         progestin pill compared with any other reversible method, including no method at all [
         <a href="#rid82">
          82
         </a>
         ]. The reason for this finding is unclear, but it may be indicative of low continuation rates for POPs in the postpartum period. Patients who prefer oral contraceptive pills may use POPs until 21 days if they have no risk factors for VTE, or until 42 days if they do have risk factors for VTE; then, they may switch to combined oral contraception if desired [
         <a href="#rid27">
          27
         </a>
         ]. As discussed below, the WHO and CDC have differing recommendations regarding the timing of initiation for both progestin-only and estrogen-containing methods [
         <a href="#rid27">
          27,28
         </a>
         ]. (See
         <a class="local">
          'Impact of contraception on breastfeeding'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Information on candidates, use, and side effects of progestin-only pills is reviewed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">
          "Contraception: Progestin-only pills (POPs)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Combined hormonal contraception (pills, patch, and vaginal ring)
         </strong>
         – CHCs include both an estrogen and a progestin. Formulations include pills, patch, and vaginal rings. CHC is not recommended until three to six weeks postpartum due to the effect of estrogen on VTE risk. (See
         <a class="local">
          'Counseling regarding venous thromboembolism risk and hormonal contraception in the postpartum period'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Detailed discussions of candidate selection, efficacy, and risks and benefits of each of the CHC methods are available separately.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7398.html" rel="external">
          "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5425.html" rel="external">
          "Contraception: Transdermal contraceptive patches"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16682.html" rel="external">
          "Contraception: Hormonal contraceptive vaginal rings"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2849742695">
         <span class="h2">
          Other
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lactational amenorrhea method
         </strong>
         – The lactational amenorrhea method (LAM) is defined as the educated use of breastfeeding as a contraceptive method while amenorrheic and not using supplementary feeding or breast pumps for up to six months after delivery. It is thought that infant suckling results in a reduction of pulsatile secretion of gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH), which in turn suppresses ovarian activity. The exact mechanism by which the suckling stimulus affects GnRH pulsatile secretion remains unknown [
         <a href="#rid20">
          20,83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Life table pregnancy rates for LAM at six months range from 0.45 to 7.5 percent (ie, 4.5 to 75 unintended pregnancies per 1000 patients exclusively using this method) in controlled and uncontrolled studies [
         <a href="#rid20">
          20
         </a>
         ]. Studies have not found clear differences in pregnancy rates between patients using LAM specifically as a contraceptive method and those who are fully breastfeeding and amenorrheic but not reporting use of any method. Thus, there is no evidence that LAM as a contraceptive method delays the recurrence of menstruation any more than exclusive breastfeeding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Promotional and training materials for LAM often advise transitioning to other contraceptive methods as soon as supplemental feeding or menstruation starts, or once the baby is older than six months. However, 20 to 56 percent of fully nursing people are not amenorrheic at six months, and many will stop exclusively breastfeeding prior to six months [
         <a href="#rid20">
          20
         </a>
         ]. Given the variable rates of patient follow-up after delivery, it seems prudent to use the first months following delivery to promote and support patients in exclusive breastfeeding for infant health, while also providing highly effective contraceptive methods as desired within the first few weeks postpartum.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pericoital methods
         </strong>
         – Pericoital methods of contraception, including diaphragms and cervical caps, are not to be used for the first six weeks postpartum, as the uterus is still undergoing involution at this time. Spermicides, the vaginal pH regulator [
         <a href="#rid84">
          84
         </a>
         ], and the contraceptive sponge may be used without restriction in the first weeks postpartum, although vaginal irritation is common with these methods. (See
         <a class="medical medical_review" href="/z/d/html/3265.html" rel="external">
          "Pericoital (on demand) contraception: Diaphragm, cervical cap, spermicides, and sponge"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Barrier methods
         </strong>
         – In the first six weeks after delivery, both female and male condoms can be used for pregnancy prevention without restriction. (See
         <a class="medical medical_review" href="/z/d/html/5471.html" rel="external">
          "Internal (formerly female) condoms"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5463.html" rel="external">
          "External (formerly male) condoms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3875781713">
         <span class="h2">
          Emergency contraception
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients who wish to avoid pregnancy should be aware of emergency contraceptive (EC) methods and when and how to access them. The
         <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">
          copper IUD
         </a>
         ,
         <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">
          levonorgestrel
         </a>
         52 mg IUDs, oral LNG, and oral
         <a class="drug drug_general" data-topicid="15626" href="/z/d/drug information/15626.html" rel="external">
          ulipristal
         </a>
         acetate (UPA) are safe for use in postpartum and breastfeeding patients [
         <a href="#rid85">
          85
         </a>
         ]. However, breastfeeding is not advised for 24 hours after taking UPA. Patients who are breastfeeding and require UPA are counseled to pump or express, and then discard, their breastmilk for 24 hours after taking UPA. Ethinyl estradiol plus LNG (Yuzpe method) should be avoided in the first three to six weeks postpartum due to possible increased risks of VTE with this method. Use of a copper IUD for EC is safe for postpartum patients [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p>
         EC options, risks and benefits, and use are presented in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5475.html" rel="external">
          "Emergency contraception"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3824527094">
         <span class="h1">
          IMPACT OF CONTRACEPTION ON BREASTFEEDING
         </span>
        </p>
        <p class="headingAnchor" id="H3831769380">
         <span class="h2">
          Copper intrauterine device
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">
          copper intrauterine device
         </a>
         (IUD) does not affect milk supply or breastfeeding [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2510931474">
         <span class="h2">
          Issues surrounding hormonal contraception during breastfeeding
         </span>
        </p>
        <p class="headingAnchor" id="H4076914546">
         <span class="h3">
          Concerns
         </span>
         <span class="headingEndMark">
          —
         </span>
         Concerns have been raised that exogenous hormones could impact lactogenesis and thereby affect breastfeeding performance (eg, breastfeeding frequency, proportion breastfeeding at different time periods), infant milk intake, or infant health outcomes (such as weight and height).
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          Progesterone
         </a>
         withdrawal after delivery initiates production of copious milk. The action of infant suckling and removal of milk increases prolactin levels, which causes alveolar cells to produce milk. This combination of suckling and elevated prolactin then prompts oxytocin levels to increase and causes alveolar contractions to release milk into the ductal system.
        </p>
        <p>
         However, concerns about the impact of hormonal contraception on lactation and breastfeeding must be balanced against the method benefits (both contraceptive and noncontraceptive) and the potential harms to the infant if breastfeeding is interrupted. As an example, for people in low-resource regions, the World Health Organization (WHO) advises exclusive breastfeeding for the first six months of life to reduce the risk of infant diarrheal illness and respiratory infection [
         <a href="#rid86">
          86
         </a>
         ]. In response to these variables and in recognition of the medical importance of breastfeeding (particularly in low-resource regions), the paucity of high-quality evidence on the effects of hormonal contraception on breastfeeding outcomes [
         <a href="#rid29">
          29,30
         </a>
         ], and the varying populations, the WHO and the Centers for Disease Control and Prevention (CDC) have published differing opinions on the timing of initiation of hormonal contraception in postpartum patients [
         <a href="#rid27">
          27,28
         </a>
         ]. The WHO
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf%3Bjsessionid%3D55C551B539A61F28BE7AE285A390FC58%3Fsequence%3D1&amp;token=prIskPfTpbcL8mRnSS6q7Hcr0tYalJMzUg36RcNANbcIemDq7OhL2c9jVDNI44wO5SbWxZcizJVzNs4c2xW37vNCZPTq4zizUxzmPhsFr8sRbLLiBIDi%2BOHm0q2FPHjjIKOEzd0EUy448DcVNjn%2Fx6d2tEQtFWHtuoephVLQgpE%3D&amp;TOPIC_ID=6708" target="_blank">
          contraceptive eligibility criteria
         </a>
         advise delaying progestin-only injectable methods to six weeks postpartum and estrogen-progestin combined methods to six months postpartum, while the CDC
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=jEVGVo6WqsDq698K1C6vDPPjIqTfzg54vW4qWS3doblDMO%2BX3NN%2Fro6R0xwK%2FI6IOwBh6DyNhV%2Fq6vrv3T8nCaRCrZsEC%2BWz9FPYFmXFzWEhd9uzeVTKQGeWKf6mT23Z1X5qsRVoFq27I5l%2B8ZoObQ%3D%3D&amp;TOPIC_ID=6708" target="_blank">
          table
         </a>
         does not advise against any hormonal contraceptive method while breastfeeding, although use of combined hormonal contraception (CHC) is delayed for at least the first three weeks after delivery because of elevated risk of venous thromboembolism (VTE) [
         <a href="#rid27">
          27,28
         </a>
         ]. (See
         <a class="local">
          'Counseling regarding venous thromboembolism risk and hormonal contraception in the postpartum period'
         </a>
         below.)
        </p>
        <p>
         The data informing the WHO and CDC statements are presented in detail below for each method. In general, the available evidence does not support a significant or consistent effect of hormonal contraception on breastfeeding outcomes. Only small amounts of estrogen and progestins are transferred to the infant through breastmilk, and data have not suggested adverse health effects of these hormones on infants [
         <a href="#rid30">
          30
         </a>
         ]. However, high-quality data are lacking, and most studies on hormonal contraception and breastfeeding have included low-risk people and those who have had success with breastfeeding prior children, or have not controlled for prior success with breastfeeding. Further research is needed on the effect of hormonal contraception on patients with preterm infants for whom breastfeeding provides additional benefits, or in patients who are primarily using breast pumps to express milk.
        </p>
        <p class="headingAnchor" id="H811224346">
         <span class="h3">
          Progestin-only methods
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Progestin-only implants
         </strong>
         – Neither the etonogestrel or
         <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">
          levonorgestrel
         </a>
         (LNG) contraceptive implants appear to have a negative effect on breastfeeding outcomes, although the available data are limited to observational studies or small trials [
         <a href="#rid87">
          87-89
         </a>
         ]. In a trial including 24 participants who received either the contraceptive implant immediately after delivery or no contraceptive method, infant milk intake, rates of exclusive breastfeeding, and newborn weights were similar between the groups at six weeks postpartum [
         <a href="#rid90">
          90
         </a>
         ]. Milk consumption was determined by having the participants ingest the stable isotope deuterium (D
         <sub>
          2
         </sub>
         O) on postpartum days 0 and 29, and then determining infant milk intake by measuring infant salivary D
         <sub>
          2
         </sub>
         O levels. A systematic review of cohort studies comparing postpartum participants using etonogestrel implants or the
         <a class="drug drug_general" data-topicid="93719" href="/z/d/drug information/93719.html" rel="external">
          copper IUD
         </a>
         did not show differences in infant growth or other infant health outcomes [
         <a href="#rid29">
          29
         </a>
         ]. In a trial comparing immediate (within five days) or delayed (six to eight weeks postpartum) insertion of the LNG implant, change in infant weight from birth to six months, time to lactogenesis, and proportion of participants who were breastfeeding exclusively did not differ between groups [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In response to these data, both the WHO
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf%3Bjsessionid%3D55C551B539A61F28BE7AE285A390FC58%3Fsequence%3D1&amp;token=prIskPfTpbcL8mRnSS6q7Hcr0tYalJMzUg36RcNANbcIemDq7OhL2c9jVDNI44wO5SbWxZcizJVzNs4c2xW37vNCZPTq4zizUxzmPhsFr8sRbLLiBIDi%2BOHm0q2FPHjjIKOEzd0EUy448DcVNjn%2Fx6d2tEQtFWHtuoephVLQgpE%3D&amp;TOPIC_ID=6708" target="_blank">
          contraceptive eligibility criteria
         </a>
         and CDC
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=jEVGVo6WqsDq698K1C6vDPPjIqTfzg54vW4qWS3doblDMO%2BX3NN%2Fro6R0xwK%2FI6IOwBh6DyNhV%2Fq6vrv3T8nCaRCrZsEC%2BWz9FPYFmXFzWEhd9uzeVTKQGeWKf6mT23Z1X5qsRVoFq27I5l%2B8ZoObQ%3D%3D&amp;TOPIC_ID=6708" target="_blank">
          table
         </a>
         agree that the advantages of progestin-only implants generally outweigh theoretical or proven risk and support immediate use of progestin-only implants in breastfeeding patients (although the timing of this label varies slightly between the groups) [
         <a href="#rid27">
          27,28
         </a>
         ]. In our practice, we routinely offer contraceptive implants to patients prior to discharge from the hospital after delivery in order to ensure access to the method.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Progestin-releasing IUDs
         </strong>
         – Studies of the LNG IUD in people who are breastfeeding have generally reported minimal to no effect on breastfeeding outcomes, and the advantages of the LNG IUD are considered by the CDC's medical eligibility criteria and WHO to outweigh any theoretical or proven risks in those who are breastfeeding [
         <a href="#rid27">
          27,87
         </a>
         ]. In a trial of 259 participants randomly assigned to immediate (postplacental) or delayed (4 to 12 weeks postpartum) insertion of an LNG IUD, no differences were reported for any breastfeeding, time to lactogenesis, exclusive breastfeeding at eight weeks, or any breastfeeding at six months postpartum [
         <a href="#rid92">
          92
         </a>
         ]. While one study limitation may have been a noninferiority margin that could have masked a true difference in the primary outcome, exploratory outcomes of breastfeeding at six months were reassuring. Due to the paucity of data on expulsion of an IUD when inserted from 48 hours to four weeks after delivery, WHO
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf%3Bjsessionid%3D55C551B539A61F28BE7AE285A390FC58%3Fsequence%3D1&amp;token=prIskPfTpbcL8mRnSS6q7Hcr0tYalJMzUg36RcNANbcIemDq7OhL2c9jVDNI44wO5SbWxZcizJVzNs4c2xW37vNCZPTq4zizUxzmPhsFr8sRbLLiBIDi%2BOHm0q2FPHjjIKOEzd0EUy448DcVNjn%2Fx6d2tEQtFWHtuoephVLQgpE%3D&amp;TOPIC_ID=6708" target="_blank">
          contraceptive eligibility criteria
         </a>
         , but not the CDC
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=jEVGVo6WqsDq698K1C6vDPPjIqTfzg54vW4qWS3doblDMO%2BX3NN%2Fro6R0xwK%2FI6IOwBh6DyNhV%2Fq6vrv3T8nCaRCrZsEC%2BWz9FPYFmXFzWEhd9uzeVTKQGeWKf6mT23Z1X5qsRVoFq27I5l%2B8ZoObQ%3D%3D&amp;TOPIC_ID=6708" target="_blank">
          table
         </a>
         , state that the theoretical or proven risks usually outweigh the advantages of using the method during this period; this restriction is unrelated to any potential effect on breastfeeding. In our practice, we offer
         <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">
          LNG IUDs
         </a>
         at any time in the postpartum period in accordance with CDC guidance and counsel regarding signs and symptoms of IUD expulsion. (See
         <a class="local">
          'Expulsion'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Progestin-only injectable
         </strong>
         – The effect of progestin-only injectable contraception on breastfeeding has been examined in clinical trials and observational studies, and most have reported either no change or improved breastfeeding outcomes for depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         (DMPA) users and generally demonstrated no harmful effects on infant growth, health, or development [
         <a href="#rid29">
          29
         </a>
         ]. However, citing a concern from animal studies that reported a possible effect of DMPA on the developing rat brain, the WHO
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf%3Bjsessionid%3D55C551B539A61F28BE7AE285A390FC58%3Fsequence%3D1&amp;token=prIskPfTpbcL8mRnSS6q7Hcr0tYalJMzUg36RcNANbcIemDq7OhL2c9jVDNI44wO5SbWxZcizJVzNs4c2xW37vNCZPTq4zizUxzmPhsFr8sRbLLiBIDi%2BOHm0q2FPHjjIKOEzd0EUy448DcVNjn%2Fx6d2tEQtFWHtuoephVLQgpE%3D&amp;TOPIC_ID=6708" target="_blank">
          contraceptive eligibility criteria
         </a>
         advise delaying initiation of DMPA in those who are lactating until six weeks postpartum [
         <a href="#rid28">
          28
         </a>
         ]. The WHO also includes a caveat in their guidance that recognizes the importance of DMPA in the immediate postpartum period in many settings where other methods are less accessible and thus supports DMPA use when that is the best option. By contrast, the CDC
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=jEVGVo6WqsDq698K1C6vDPPjIqTfzg54vW4qWS3doblDMO%2BX3NN%2Fro6R0xwK%2FI6IOwBh6DyNhV%2Fq6vrv3T8nCaRCrZsEC%2BWz9FPYFmXFzWEhd9uzeVTKQGeWKf6mT23Z1X5qsRVoFq27I5l%2B8ZoObQ%3D%3D&amp;TOPIC_ID=6708" target="_blank">
          table
         </a>
         states that immediate use of DMPA generally outweighs any proven or theoretical concerns and that it can be used without restriction in those who are breastfeeding more than 30 days postpartum [
         <a href="#rid27">
          27
         </a>
         ]. In our practice, we offer DMPA at any time in the postpartum period, including immediately after delivery, in accordance with CDC guidance as we believe the benefits outweigh any theoretical risks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Progestin-only pills
         </strong>
         – Both trial and observational data generally support the use of progestin-only pills (POPs) in the postpartum period [
         <a href="#rid29">
          29,93,94
         </a>
         ]. One trial of nearly 130 participants reported no differences in breastfeeding continuation or supplementation at six months postpartum for participants using POPs compared with combined oral contraceptive pills [
         <a href="#rid94">
          94
         </a>
         ]. In a systematic review of eight observational studies including those who started POPs in the first six weeks postpartum, POP users had either no difference or improved breastfeeding outcomes compared with nonusers; study outcomes included breastfeeding initiation, breastfeeding duration, or use of supplementation [
         <a href="#rid29">
          29
         </a>
         ]. Both the WHO and the CDC agree that people who are breastfeeding less than six weeks postpartum can use POPs, as the benefits appear to outweigh the risks. Beyond six weeks, there are no restrictions [
         <a href="#rid27">
          27,28
         </a>
         ]. In our practice, we offer POPs at any time during the postpartum period in accordance with CDC and WHO guidance.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3347351865">
         <span class="h3">
          Combined estrogen-progestin methods
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, studies assessing the impact of CHCs (pills, patch, vaginal ring) on breastfeeding duration and success have reported inconsistent data. In a 2015 meta-analysis that included four trials of combined oral contraceptive pills, one trial reported a negative effect on breastfeeding duration while the other three trials did not assess this outcome [
         <a href="#rid95">
          95
         </a>
         ]. Two trials reported lower breast milk volume for oral CHC users compared with placebo; one trial did not quantify results, and the other reported lower mean volumes that were unlikely to be clinically meaningful. In a trial performed after the meta-analysis that assessed participants who initiated their desired contraceptive method on postpartum day 42, infant breast milk intake and growth were similar between participants using hormonal and nonhormonal contraception [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The WHO
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf%3Bjsessionid%3D55C551B539A61F28BE7AE285A390FC58%3Fsequence%3D1&amp;token=prIskPfTpbcL8mRnSS6q7Hcr0tYalJMzUg36RcNANbcIemDq7OhL2c9jVDNI44wO5SbWxZcizJVzNs4c2xW37vNCZPTq4zizUxzmPhsFr8sRbLLiBIDi%2BOHm0q2FPHjjIKOEzd0EUy448DcVNjn%2Fx6d2tEQtFWHtuoephVLQgpE%3D&amp;TOPIC_ID=6708" target="_blank">
          contraceptive eligibility criteria
         </a>
         advise delaying use of estrogen-containing methods until six months postpartum for those who are primarily breastfeeding because of the importance of breastfeeding on infant health in low-resource settings [
         <a href="#rid28">
          28
         </a>
         ]. They advise people who desire CHCs to begin other progestin-only or nonhormonal methods until CHC is initiated. (See
         <a class="local">
          'Impact of contraception on breastfeeding'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As presented in the CDC contraceptive
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=jEVGVo6WqsDq698K1C6vDPPjIqTfzg54vW4qWS3doblDMO%2BX3NN%2Fro6R0xwK%2FI6IOwBh6DyNhV%2Fq6vrv3T8nCaRCrZsEC%2BWz9FPYFmXFzWEhd9uzeVTKQGeWKf6mT23Z1X5qsRVoFq27I5l%2B8ZoObQ%3D%3D&amp;TOPIC_ID=6708" target="_blank">
          table
         </a>
         , CHC should be avoided until at least 30 days postpartum due to the increased risk of VTE [
         <a href="#rid27">
          27
         </a>
         ]. Breastfeeding people who do not have additional VTE risk factors may reasonably begin CHC at 30 days postpartum. However, breastfeeding people with additional VTE risk factors should delay CHC initiation until at least 42 days (six weeks) postpartum.
        </p>
        <p>
        </p>
        <p>
         Consistent with CDC guidance, we avoid prescribing CHCs for the first three to six weeks postpartum due to increased risk of VTE in the postpartum period (timing of initiation varies based on VTE risk factors). After three to six weeks postpartum, breastfeeding is generally established, and we offer CHC to postpartum patients who are appropriate medical candidates consistent with the CDC medical eligibility criteria [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="local">
          'Counseling regarding venous thromboembolism risk and hormonal contraception in the postpartum period'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1807806046">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pericoital and barrier methods of contraception do not impact milk supply or breastfeeding.
        </p>
        <p class="headingAnchor" id="H2769258718">
         <span class="h1">
          COUNSELING REGARDING VENOUS THROMBOEMBOLISM RISK AND HORMONAL CONTRACEPTION IN THE POSTPARTUM PERIOD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients in the postpartum period have a higher risk of VTE compared with both nonpregnant, nonpostpartum patients and pregnant patients. Normal hematologic changes in the postpartum period include increasing coagulation factors and fibrinogen, and decreasing natural anticoagulants protein S and protein C, which likely occur to prevent hemorrhage after delivery. (See
         <a class="medical medical_review" href="/z/d/html/429.html" rel="external">
          "Maternal adaptations to pregnancy: Hematologic changes", section on 'Coagulation and fibrinolysis'
         </a>
         .)
        </p>
        <p>
         As there are few studies evaluating the incidence of venous thromboembolism (VTE) in postpartum patients using combined hormonal contraceptives (CHCs) or progestin-only contraceptives, risk is extrapolated from both postpartum and nonpostpartum patients.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Baseline postpartum VTE risk
         </strong>
         – A systematic review estimated that the risk of VTE is as much as five times higher during the postpartum period compared with pregnancy itself, and during the first six weeks postpartum, patients' risk of VTE increases 21- to 84-fold from baseline [
         <a href="#rid97">
          97
         </a>
         ]. The systematic review further reported the incidence rate of VTE was 357.3 in week 1, decreased weekly through the first six postpartum weeks to 31.5, and then plateaued at 3.2 in postpartum weeks 7 to 12.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Combined hormonal contraception
         </strong>
         – The risk of VTE associated with CHC use in healthy nonpregnant patients is three to seven times higher than in nonusers, and thus, use of CHCs for the initial three to six weeks postpartum is generally contraindicated [
         <a href="#rid27">
          27,28,97
         </a>
         ]. Detailed discussion of VTE risk specific to estrogen-containing contraception is presented in related content. (See
         <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">
          "Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Venous thromboembolism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Progestin-only contraception
         </strong>
         – Most evidence does not suggest an increase in odds for venous or arterial thromboembolic events with the use of progestin-only oral or implantable contraceptives. A database study comparing over 8300 individuals who received an
         <a class="drug drug_general" data-topicid="8870" href="/z/d/drug information/8870.html" rel="external">
          etonogestrel implant
         </a>
         during the delivery admission with unexposed postpartum individuals reported similar 30-day readmission rates for VTE for both groups (adjusted odds ratio 1.81, 95% CI 0.44-7.45) [
         <a href="#rid98">
          98
         </a>
         ]. While several studies have reported an increased risk of VTE with the use of progestin-only injections, the absolute incidence remains low [
         <a href="#rid81">
          81,99,100
         </a>
         ]. Both the World Health Organization and the Centers for Disease Control and Prevention advise that the data supporting immediate use of progestin-only contraception generally outweigh the risks, either established or theoretical [
         <a href="#rid27">
          27,28
         </a>
         ]. Additional discussions of VTE risk specific to progestin-only contraceptives are presented in separately.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">
          "Contraception: Etonogestrel implant", section on 'Risk of thromboembolic event'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">
          "Contraception: Progestin-only pills (POPs)", section on 'Risks'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H133067424">
         <span class="h1">
          SPECIAL POPULATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adolescents
         </strong>
         – Selection of contraception for postpartum teens and young adults does not differ from that of older patients. Issues specific to adolescents are discussed separately. Access to long-acting reversible contraceptives, including implants and intrauterine devices, immediately after delivery has been shown to increase time to next pregnancy in adolescents and is an important public health intervention in this age group [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/107.html" rel="external">
          "Contraception: Issues specific to adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with depression and related disorders
         </strong>
         – Hormonal contraception, both estrogen-progestin and progestin-only methods, can be used by patients with depressive disorders (either preexisting or postpartum) [
         <a href="#rid27">
          27,28
         </a>
         ]. There are no restrictions for this use of hormonal contraception in this population in both the Centers for Disease Control and Prevention (CDC)
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=jEVGVo6WqsDq698K1C6vDPPjIqTfzg54vW4qWS3doblDMO%2BX3NN%2Fro6R0xwK%2FI6IOwBh6DyNhV%2Fq6vrv3T8nCaRCrZsEC%2BWz9FPYFmXFzWEhd9uzeVTKQGeWKf6mT23Z1X5qsRVoFq27I5l%2B8ZoObQ%3D%3D&amp;TOPIC_ID=6708" target="_blank">
          table
         </a>
         and World Health Organization (WHO)
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf%3Bjsessionid%3D55C551B539A61F28BE7AE285A390FC58%3Fsequence%3D1&amp;token=prIskPfTpbcL8mRnSS6q7Hcr0tYalJMzUg36RcNANbcIemDq7OhL2c9jVDNI44wO5SbWxZcizJVzNs4c2xW37vNCZPTq4zizUxzmPhsFr8sRbLLiBIDi%2BOHm0q2FPHjjIKOEzd0EUy448DcVNjn%2Fx6d2tEQtFWHtuoephVLQgpE%3D&amp;TOPIC_ID=6708" target="_blank">
          contraceptive eligibility criteria
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a systematic review that included 26 studies, no clear relationship was noted between progestin contraceptives and depression scores or incident diagnoses [
         <a href="#rid101">
          101
         </a>
         ]. Some studies evaluating the effect on mood of depot
         <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">
          medroxyprogesterone acetate
         </a>
         (DMPA) in postpartum patients have suggested that injectable progestin-only contraception may increase depression scores temporarily in postpartum patients; however, data are not robust [
         <a href="#rid79">
          79,102
         </a>
         ], and other studies have reported conflicting results [
         <a href="#rid80">
          80
         </a>
         ]. We believe that the data are conflicting enough that providers should not restrict DMPA postpartum in those patients who desire it. Counseling on method risks should be comprehensive, and screening for postpartum depression should occur regardless of contraceptive method chosen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medical illness
         </strong>
         – Patients with comorbid medical conditions should be offered contraceptive methods in accordance with the WHO
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fapps.who.int%2Firis%2Fbitstream%2Fhandle%2F10665%2F181468%2F9789241549158_eng.pdf%3Bjsessionid%3D55C551B539A61F28BE7AE285A390FC58%3Fsequence%3D1&amp;token=prIskPfTpbcL8mRnSS6q7Hcr0tYalJMzUg36RcNANbcIemDq7OhL2c9jVDNI44wO5SbWxZcizJVzNs4c2xW37vNCZPTq4zizUxzmPhsFr8sRbLLiBIDi%2BOHm0q2FPHjjIKOEzd0EUy448DcVNjn%2Fx6d2tEQtFWHtuoephVLQgpE%3D&amp;TOPIC_ID=6708" target="_blank">
          contraceptive eligibility criteria
         </a>
         , or other relevant national guidance. Mobile
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fmmwr%2Fmec%2Fsummary.html&amp;token=gn9CxBU9SK4%2Bjug8DleFYAmCahKbgv18S9Zgv5fBNxTGoMdTGRC8XnfLV%2BmDF%2FKgq%2FUbcwPNhHygS%2BUPWWe15o2kSqIPMCtrmL2KJwaUlwQ%3D&amp;TOPIC_ID=6708" target="_blank">
          applications
         </a>
         are readily available for quick reference regarding patients' eligibility for contraceptive methods based on comorbid conditions, including patients with thromboembolic disease, hypertension, diabetes, headache, HIV infection, obesity, pelvic infection, and seizure disorders.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients taking other medications should be offered contraceptive methods in accordance with CDC, WHO, or other relevant national guidance. Mobile
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fmmwr%2Fmec%2Fsummary.html&amp;token=gn9CxBU9SK4%2Bjug8DleFYAmCahKbgv18S9Zgv5fBNxTGoMdTGRC8XnfLV%2BmDF%2FKgq%2FUbcwPNhHygS%2BUPWWe15o2kSqIPMCtrmL2KJwaUlwQ%3D&amp;TOPIC_ID=6708" target="_blank">
          applications
         </a>
         are readily available for quick reference regarding patients' eligibility for contraceptive methods based on concurrent use of anticonvulsants, antimicrobials, or antiretrovirals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Obese patients
         </strong>
         – Obese patients (ie, body mass index ≥30 kg/m
         <sup>
          2
         </sup>
         ) may have additional medical comorbidities or higher risk of venous thromboembolism that can impact their choice of postpartum contraception. Issues specific to obese patients who desire effective contraception, including method efficacy, are addressed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5470.html" rel="external">
          "Contraception: Counseling for females with obesity"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H860159341">
         <span class="h1">
          PATIENTS WHO ARE UNDECIDED ABOUT CONTRACEPTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who are undecided about contraception at any point during pregnancy or postpartum should be counseled regarding all of their options and given written support materials on contraceptive methods. Patients can be counseled on the effect on fertility of exclusive breastfeeding, as well as the risk of ovulation within the first four to six weeks postpartum. In addition, patients should be given comprehensive information on emergency contraception. Consistent with the American College of Obstetricians and Gynecologists, we believe that contact with a provider during the postpartum period should be a process rather than a discrete visit and should occur at least once in the one to three weeks postpartum, with individualization of ongoing follow-up as needed [
         <a href="#rid2">
          2
         </a>
         ]. Thus, contraception can and should be addressed at more than one time point in the postpartum period if needed. However, patients should not be made to feel pressured to choose a method if they are undecided or would prefer behavioral methods of pregnancy prevention such as abstinence, withdrawal, lactational amenorrhea method, or fertility awareness methods. (See
         <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">
          "Contraception: Counseling and selection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2769032174">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112268.html" rel="external">
          "Society guideline links: Contraception"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/123007.html" rel="external">
          "Society guideline links: Postpartum care"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3942014651">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/8421.html" rel="external">
          "Patient education: Birth control; which method is right for me? (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2262628828">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Return of ovulation
         </strong>
         – In a systematic review of studies estimating the time to return to fertility in nonlactating postpartum participants, the average time to first ovulation varied from 45 to 94 days postpartum, with the earliest ovulation reported at 25 days postpartum. (See
         <a class="local">
          'Resumption of ovulation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraceptive counseling points
         </strong>
         – For counseling people about contraception, we use a patient-centered, shared decision-making model. Key components to discuss include the patient's reproductive life plan, desired characteristics of contraceptives, medical issues or comorbidities, and plans for breastfeeding. (See
         <a class="local">
          'Our approach to counseling'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who are undecided about contraception at any point during pregnancy or postpartum are counseled regarding all of their options and given written support materials on contraceptive methods, including emergency contraception. (See
         <a class="local">
          'Emergency contraception'
         </a>
         above and
         <a class="local">
          'Patients who are undecided about contraception'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraceptives for immediate postpartum use
         </strong>
         – Contraceptive methods that can be initiated immediately after delivery include female and male permanent contraception, progestin-only implants, intrauterine devices (IUD; copper or
         <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">
          levonorgestrel
         </a>
         ), the progestin injection, and the progestin-only pill. (See
         <a class="local">
          'Permanent contraception'
         </a>
         above and
         <a class="local">
          'Progestin-only implants'
         </a>
         above and
         <a class="local">
          'Intrauterine devices'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Timing options for IUD placement
         </strong>
         – For those who desire an IUD after delivery, explicit counseling should center on timing of IUD placement. IUD insertion timing can be postplacental, delayed, or interval. Risks (eg, expulsion and perforation) and benefits (eg, effectiveness) vary by timing of IUD placement after delivery. (See
         <a class="local">
          'Options for timing of placementafter delivery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Risks and benefits of postpartum IUD placement
         </strong>
         – Issues that we discuss with patients who desire a postpartum intrauterine device include the risks of IUD expulsion, perforation of the uterus, and IUD malposition. Despite these concerns, the odds of using an IUD six months after delivery is twice as high for those who receive a postplacental IUD as compared with interval placement. (See
         <a class="local">
          'Issues related to postpartum IUD placement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Delayed start of estrogen-containing contraceptives
         </strong>
         – For those who desire short-acting combined estrogen-progestin contraception, the oral pill, transdermal patch, and vaginal ring should not be started earlier than 21 days postpartum for anyone because of the increased risk of venous thromboembolism (VTE). (See
         <a class="local">
          'Short-acting hormonal contraception'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact of postpartum contraception
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Lactation
         </strong>
         – In general, the progestin-only methods appear to have minimal to no effect on breastfeeding outcomes. Studies assessing the impact of combined hormonal contraceptives (CHCs; pills, patch, vaginal ring) on breastfeeding duration and success have reported inconsistent data. The Centers for Disease Control and Prevention and the World Health Organization recommendations about hormonal contraceptives and breastfeeding differ. (See
         <a class="local">
          'Issues surrounding hormonal contraception during breastfeeding'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          VTE risk
         </strong>
         – No studies have evaluated the incidence of VTE in postpartum patients using CHCs or progestin-only contraceptives. However, the risk of VTE associated with CHC use in healthy nonpregnant patients is three to seven times higher than in nonusers, and thus use of CHC for the initial three to six weeks postpartum is generally contraindicated. (See
         <a class="local">
          'Counseling regarding venous thromboembolism risk and hormonal contraception in the postpartum period'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H504400615">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Andrew M. Kaunitz, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Jackson E, Glasier A. Return of ovulation and menses in postpartum nonlactating women: a systematic review. Obstet Gynecol 2011; 117:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACOG Committee Opinion No. 736: Optimizing Postpartum Care. Obstet Gynecol 2018; 131:e140. Reaffirmed 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sonalkar S, Hunter T, Gurney EP, et al. A Decision Analysis Model of 1-Year Effectiveness of Intended Postplacental Compared With Intended Delayed Postpartum Intrauterine Device Insertion. Obstet Gynecol 2018; 132:1211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrd JE, Hyde JS, DeLamater JD, Plant EA. Sexuality during pregnancy and the year postpartum. J Fam Pract 1998; 47:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers RG, Borders N, Leeman LM, Albers LL. Does spontaneous genital tract trauma impact postpartum sexual function? J Midwifery Womens Health 2009; 54:98.
          </a>
         </li>
         <li class="breakAll">
          Report of a WHO Technical Consultation on Birth Spacing. World Health Organization, Geneva, Switzerland, June 13-15, 2005.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahrens KA, Nelson H, Stidd RL, et al. Short interpregnancy intervals and adverse perinatal outcomes in high-resource settings: An updated systematic review. Paediatr Perinat Epidemiol 2019; 33:O25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DaVanzo J, Hale L, Razzaque A, Rahman M. Effects of interpregnancy interval and outcome of the preceding pregnancy on pregnancy outcomes in Matlab, Bangladesh. BJOG 2007; 114:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DaVanzo J, Hale L, Razzaque A, Rahman M. The effects of pregnancy spacing on infant and child mortality in Matlab, Bangladesh: how they vary by the type of pregnancy outcome that began the interval. Popul Stud (Camb) 2008; 62:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cleland J, Shah IH, Benova L. A Fresh Look at the Level of Unmet Need for Family Planning in the Postpartum Period, Its Causes and Program Implications. Int Perspect Sex Reprod Health 2015; 41:155.
          </a>
         </li>
         <li class="breakAll">
          Ross J, Winfrey W. Contraceptive Use, Intention to Use and Unmet Need During the Extended Postpartum Period. Int Fam Plann Persp 2001; 27:20.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossier C, Bradley SE, Ross J, Winfrey W. Reassessing Unmet Need for Family Planning in the Postpartum Period. Stud Fam Plann 2015; 46:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunson MR, Klein DA, Olsen CH, et al. Postpartum contraception: initiation and effectiveness in a large universal healthcare system. Am J Obstet Gynecol 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damle LF, Gohari AC, McEvoy AK, et al. Early initiation of postpartum contraception: does it decrease rapid repeat pregnancy in adolescents? J Pediatr Adolesc Gynecol 2015; 28:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gifford K, McDuffie MJ, Rashid H, et al. Postpartum contraception method type and risk of a short interpregnancy interval in a state Medicaid population. Contraception 2021; 104:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steenland MW, Vatsa R, Pace LE, Cohen JL. Immediate Postpartum Long-Acting Reversible Contraceptive Use Following State-Specific Changes in Hospital Medicaid Reimbursement. JAMA Netw Open 2022; 5:32237918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steenland MW, Pace LE, Sinaiko AD, Cohen JL. Association Between South Carolina Medicaid's Change in Payment for Immediate Postpartum Long-Acting Reversible Contraception and Birth Intervals. JAMA 2019; 322:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steenland MW, Pace LE, Cohen JL. Association of Medicaid Reimbursement for Immediate Postpartum Long-acting Reversible Contraception With Infant Birth Outcomes. JAMA Pediatr 2022; 176:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thurman AR, Janecek T. One-year follow-up of women with unfulfilled postpartum sterilization requests. Obstet Gynecol 2010; 116:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van der Wijden C, Manion C. Lactational amenorrhoea method for family planning. Cochrane Database Syst Rev 2015; :CD001329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dehlendorf C, Grumbach K, Schmittdiel JA, Steinauer J. Shared decision making in contraceptive counseling. Contraception 2017; 95:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hapenney S. Divergent practices among Catholic hospitals in provision of direct sterilization. Linacre Q 2013; 80:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guiahi M, Sheeder J, Teal S. Are women aware of religious restrictions on reproductive health at Catholic hospitals? A survey of women's expectations and preferences for family planning care. Contraception 2014; 90:429.
          </a>
         </li>
         <li class="breakAll">
          Envision Sexual and Reproductive Health. PATH questions. https://www.envisionsrh.com/path-questions-examples (Accessed on November 20, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teal SB, Sheeder J. Balancing the Risks and Desires for Pregnancy in Older Mothers: Increasing Morbidity, Declining Fertility. JAMA Intern Med 2018; 178:1671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson AV, Karasek D, Dehlendorf C, Foster DG. Racial and ethnic differences in women's preferences for features of contraceptive methods. Contraception 2016; 93:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.
          </a>
         </li>
         <li class="breakAll">
          Medical Eligibility Criteria for Contraceptive Use, 5th ed, World Health Organization,  Geneva 2015.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips SJ, Tepper NK, Kapp N, et al. Progestogen-only contraceptive use among breastfeeding women: a systematic review. Contraception 2016; 94:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tepper NK, Phillips SJ, Kapp N, et al. Combined hormonal contraceptive use among breastfeeding women: an updated systematic review. Contraception 2016; 94:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bryant AG, Lyerly AD, DeVane-Johnson S, et al. Hormonal contraception, breastfeeding and bedside advocacy: the case for patient-centered care. Contraception 2019; 99:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zite N, Wuellner S, Gilliam M. Failure to obtain desired postpartum sterilization: risk and predictors. Obstet Gynecol 2005; 105:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albanese A, French M, Gossett DR. Request and fulfillment of postpartum tubal ligation in patients after high-risk pregnancy. Contraception 2017; 95:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolfe KK, Wilson MD, Hou MY, Creinin MD. An updated assessment of postpartum sterilization fulfillment after vaginal delivery. Contraception 2017; 96:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guiahi M, McNulty M, Garbe G, et al. Changing depot medroxyprogesterone acetate access at a faith-based institution. Contraception 2011; 84:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stern AM. Sterilized in the name of public health: race, immigration, and reproductive control in modern California. Am J Public Health 2005; 95:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hevia M, Constantin A. Gendered Power Relations and Informed Consent: The I.V. v. Bolivia Case. Health Hum Rights 2018; 20:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reilly PR. Eugenics and Involuntary Sterilization: 1907-2015. Annu Rev Genomics Hum Genet 2015; 16:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kendall T, Albert C. Experiences of coercion to sterilize and forced sterilization among women living with HIV in Latin America. J Int AIDS Soc 2015; 18:19462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atkinson HG, Ottenheimer D. Involuntary sterilization among HIV-positive Garifuna women from Honduras seeking asylum in the United States: Two case reports. J Forensic Leg Med 2018; 56:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borrero S, Zite N, Potter JE, Trussell J. Medicaid policy on sterilization--anachronistic or still relevant? N Engl J Med 2014; 370:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Natavio MF, Cortessis VK, Zite NB, et al. The use of a low-literacy version of the Medicaid sterilization consent form to assess sterilization-related knowledge in Spanish-speaking women: results from a randomized controlled trial. Contraception 2018; 97:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitaker AK, Chen BA. Society of Family Planning Guidelines: Postplacental insertion of intrauterine devices. Contraception 2018; 97:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sonalkar S, Kapp N. Intrauterine device insertion in the postpartum period: a systematic review. Eur J Contracept Reprod Health Care 2015; 20:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez LM, Bernholc A, Hubacher D, et al. Immediate postpartum insertion of intrauterine device for contraception. Cochrane Database Syst Rev 2015; :CD003036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caliskan E, Oztürk N, Dilbaz BO, Dilbaz S. Analysis of risk factors associated with uterine perforation by intrauterine devices. Eur J Contracept Reprod Health Care 2003; 8:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen BA, Reeves MF, Hayes JL, et al. Postplacental or delayed insertion of the levonorgestrel intrauterine device after vaginal delivery: a randomized controlled trial. Obstet Gynecol 2010; 116:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitaker AK, Endres LK, Mistretta SQ, Gilliam ML. Postplacental insertion of the levonorgestrel intrauterine device after cesarean delivery vs. delayed insertion: a randomized controlled trial. Contraception 2014; 89:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lester F, Kakaire O, Byamugisha J, et al. Intracesarean insertion of the Copper T380A versus 6 weeks postcesarean: a randomized clinical trial. Contraception 2015; 91:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levi EE, Stuart GS, Zerden ML, et al. Intrauterine Device Placement During Cesarean Delivery and Continued Use 6 Months Postpartum: A Randomized Controlled Trial. Obstet Gynecol 2015; 126:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elsedeek MS. Puerperal and menstrual bleeding patterns with different types of contraceptive device fitted during elective cesarean delivery. Int J Gynaecol Obstet 2012; 116:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welkovic S, Costa LO, Faúndes A, et al. Post-partum bleeding and infection after post-placental IUD insertion. Contraception 2001; 63:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilcox A, Levi EE, Garrett JM. Predictors of Non-Attendance to the Postpartum Follow-up Visit. Matern Child Health J 2016; 20:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen MJ, Hsia JK, Hou MY, et al. Comparing Postpartum Visit Attendance with a Scheduled 2- to 3-Week or 6-Week Visit after Delivery. Am J Perinatol 2019; 36:936.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jatlaoui TC, Whiteman MK, Jeng G, et al. Intrauterine Device Expulsion After Postpartum Placement: A Systematic Review and Meta-analysis. Obstet Gynecol 2018; 132:895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen R, Sheeder J, Arango N, et al. Twelve-month contraceptive continuation and repeat pregnancy among young mothers choosing postdelivery contraceptive implants or postplacental intrauterine devices. Contraception 2016; 93:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chi IC, Wilkens L, Rogers S. Expulsions in immediate postpartum insertions of Lippes Loop D and Copper T IUDs and their counterpart Delta devices--an epidemiological analysis. Contraception 1985; 32:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stuart GS, Lesko CR, Stuebe AM, et al. A randomized trial of levonorgestrel intrauterine system insertion 6 to 48 h compared to 6 weeks after vaginal delivery; lessons learned. Contraception 2015; 91:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aoun J, Dines VA, Stovall DW, et al. Effects of age, parity, and device type on complications and discontinuation of intrauterine devices. Obstet Gynecol 2014; 123:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madden T, McNicholas C, Zhao Q, et al. Association of age and parity with intrauterine device expulsion. Obstet Gynecol 2014; 124:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hinz EK, Murthy A, Wang B, et al. A prospective cohort study comparing expulsion after postplacental insertion: the levonorgestrel versus the copper intrauterine device. Contraception 2019; 100:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Averbach SH, Ermias Y, Jeng G, et al. Expulsion of intrauterine devices after postpartum placement by timing of placement, delivery type, and intrauterine device type: a systematic review and meta-analysis. Am J Obstet Gynecol 2020; 223:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armstrong MA, Raine-Bennett T, Reed SD, et al. Association of the Timing of Postpartum Intrauterine Device Insertion and Breastfeeding With Risks of Intrauterine Device Expulsion. JAMA Netw Open 2022; 5:e2148474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mishell DR Jr, Roy S. Copper intrauterine contraceptive device event rates following insertion 4 to 8 weeks post partum. Am J Obstet Gynecol 1982; 143:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Averbach S, Kully G, Hinz E, et al. Early vs Interval Postpartum Intrauterine Device Placement: A Randomized Clinical Trial. JAMA 2023; 329:910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez OP, Wilder L, Seal P. Ultrasound-Guided Compared With Non-Ultrasound-Guided Placement of Immediate Postpartum Intrauterine Contraceptive Devices. Obstet Gynecol 2022; 140:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurney EP, Sonalkar S, McAllister A, et al. Six-month expulsion of postplacental copper intrauterine devices placed after vaginal delivery. Am J Obstet Gynecol 2018; 219:183.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Rivera M, Averbach S, Selvaduray P, et al. Complications after interval postpartum intrauterine device insertion. Am J Obstet Gynecol 2022; 226:95.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baldwin MK, Edelman AB, Lim JY, et al. Intrauterine device placement at 3 versus 6 weeks postpartum: a randomized trial. Contraception 2016; 93:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anthony MS, Reed SD, Armstrong MA, et al. Design of the Association of Uterine Perforation and Expulsion of Intrauterine Device study: a multisite retrospective cohort study. Am J Obstet Gynecol 2021; 224:599.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berry-Bibee EN, Tepper NK, Jatlaoui TC, et al. The safety of intrauterine devices in breastfeeding women: a systematic review. Contraception 2016; 94:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heinemann K, Barnett C, Reed S, et al. IUD use among parous women and risk of uterine perforation: a secondary analysis. Contraception 2017; 95:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowe P, Farley T, Peregoudov A, et al. Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: A 7-year randomized comparative study with the TCu380A. Contraception 2016; 93:498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braaten KP, Benson CB, Maurer R, Goldberg AB. Malpositioned intrauterine contraceptive devices: risk factors, outcomes, and future pregnancies. Obstet Gynecol 2011; 118:1014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sivin I, Shaaban M, Odlind V, et al. A randomized trial of the Gyne T 380 and Gyne T 380 Slimline Intrauterine Copper devices. Contraception 1990; 42:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bahamondes L, Díaz J, Petta C, et al. Comparison of the performances of TCu380A and TCu380S IUDs up to five years. Adv Contracept 1999; 15:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blumenthal PD, Lerma K, Bhamrah R, et al. Comparative safety and efficacy of a dedicated postpartum IUD inserter versus forceps for immediate postpartum IUD insertion: a randomized trial. Contraception 2018; 98:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colwill AC, Schreiber CA, Sammel MD, Sonalkar S. Six-week retention after postplacental copper intrauterine device placement. Contraception 2018; 97:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singata-Madliki M, Hofmeyr GJ, Lawrie TA. The effect of depot medroxyprogesterone acetate on postnatal depression: a randomised controlled trial. J Fam Plann Reprod Health Care 2016; 42:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsai R, Schaffir J. Effect of depot medroxyprogesterone acetate on postpartum depression. Contraception 2010; 82:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tepper NK, Jeng G, Curtis KM, et al. Venous Thromboembolism Among Women Initiating Depot Medroxyprogesterone Acetate Immediately Postpartum. Obstet Gynecol 2019; 133:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sackeim MG, Gurney EP, Koelper N, et al. Effect of contraceptive choice on rapid repeat pregnancy. Contraception 2019; 99:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNeilly AS, Tay CC, Glasier A. Physiological mechanisms underlying lactational amenorrhea. Ann N Y Acad Sci 1994; 709:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas MA, Chappell BT, Maximos B, et al. A novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trial. Contracept X 2020; 2:100031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.
          </a>
         </li>
         <li class="breakAll">
          Horta BL, Victora CG. Short-term effects of breastfeeding: A systematic review on the benefits of breastfeeding on diarrhoea and pneumonia mortality. World Health Organization http://apps.who.int/iris/bitstream/handle/10665/95585/9789241506120_eng.pdf?sequence=1 (Accessed on January 07, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stanton TA, Blumenthal PD. Postpartum hormonal contraception in breastfeeding women. Curr Opin Obstet Gynecol 2019; 31:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henkel A, Lerma K, Reyes G, et al. Lactogenesis and breastfeeding after immediate versus delayed birth-hospitalization insertion of etonogestrel contraceptive implant: A non-inferiority trial. Am J Obstet Gynecol 2022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henkel A, Lerma K, Reyes G, et al. Lactogenesis and breastfeeding after immediate vs delayed birth-hospitalization insertion of etonogestrel contraceptive implant: a noninferiority trial. Am J Obstet Gynecol 2023; 228:55.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braga GC, Ferriolli E, Quintana SM, et al. Immediate postpartum initiation of etonogestrel-releasing implant: A randomized controlled trial on breastfeeding impact. Contraception 2015; 92:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Averbach S, Kakaire O, McDiehl R, et al. The effect of immediate postpartum levonorgestrel contraceptive implant use on breastfeeding and infant growth: a randomized controlled trial. Contraception 2019; 99:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turok DK, Leeman L, Sanders JN, et al. Immediate postpartum levonorgestrel intrauterine device insertion and breast-feeding outcomes: a noninferiority randomized controlled trial. Am J Obstet Gynecol 2017; 217:665.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giner Velázquez J, Cortés Gallegos V, Sotelo López A, Bondani G. [Effect of daily oral administration of 0.350 mg of norethindrone on lactation and on the composition of milk]. Ginecol Obstet Mex 1976; 40:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espey E, Ogburn T, Leeman L, et al. Effect of progestin compared with combined oral contraceptive pills on lactation: a randomized controlled trial. Obstet Gynecol 2012; 119:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez LM, Grey TW, Stuebe AM, et al. Combined hormonal versus nonhormonal versus progestin-only contraception in lactation. Cochrane Database Syst Rev 2015; :CD003988.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bahamondes L, Bahamondes MV, Modesto W, et al. Effect of hormonal contraceptives during breastfeeding on infant's milk ingestion and growth. Fertil Steril 2013; 100:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson E, Curtis KM, Gaffield ME. Risk of venous thromboembolism during the postpartum period: a systematic review. Obstet Gynecol 2011; 117:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Floyd JL, Beasley AD, Swaim LS, et al. Association of Immediate Postpartum Etonogestrel Implant Insertion and Venous Thromboembolism. Obstet Gynecol 2020; 135:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergendal A, Persson I, Odeberg J, et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol 2014; 124:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010; 30:2297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Worly BL, Gur TL, Schaffir J. The relationship between progestin hormonal contraception and depression: a systematic review. Contraception 2018; 97:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawrie TA, Hofmeyr GJ, De Jager M, et al. A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. Br J Obstet Gynaecol 1998; 105:1082.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6708 Version 115.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21343770" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Return of ovulation and menses in postpartum nonlactating women: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29683911" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : ACOG Committee Opinion No. 736: Optimizing Postpartum Care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30303909" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A Decision Analysis Model of 1-Year Effectiveness of Intended Postplacental Compared With Intended Delayed Postpartum Intrauterine Device Insertion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9789517" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Sexuality during pregnancy and the year postpartum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19249654" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Does spontaneous genital tract trauma impact postpartum sexual function?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19249654" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Does spontaneous genital tract trauma impact postpartum sexual function?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30353935" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Short interpregnancy intervals and adverse perinatal outcomes in high-resource settings: An updated systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17617195" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Effects of interpregnancy interval and outcome of the preceding pregnancy on pregnancy outcomes in Matlab, Bangladesh.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18587691" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The effects of pregnancy spacing on infant and child mortality in Matlab, Bangladesh: how they vary by the type of pregnancy outcome that began the interval.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26600569" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A Fresh Look at the Level of Unmet Need for Family Planning in the Postpartum Period, Its Causes and Program Implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26600569" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A Fresh Look at the Level of Unmet Need for Family Planning in the Postpartum Period, Its Causes and Program Implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26643487" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Reassessing Unmet Need for Family Planning in the Postpartum Period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28257962" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Postpartum contraception: initiation and effectiveness in a large universal healthcare system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25555302" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Early initiation of postpartum contraception: does it decrease rapid repeat pregnancy in adolescents?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34023380" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Postpartum contraception method type and risk of a short interpregnancy interval in a state Medicaid population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Immediate Postpartum Long-Acting Reversible Contraceptive Use Following State-Specific Changes in Hospital Medicaid Reimbursement
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31158852" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Association Between South Carolina Medicaid's Change in Payment for Immediate Postpartum Long-Acting Reversible Contraception and Birth Intervals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35006260" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Association of Medicaid Reimbursement for Immediate Postpartum Long-acting Reversible Contraception With Infant Birth Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20966691" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : One-year follow-up of women with unfulfilled postpartum sterilization requests.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26457821" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Lactational amenorrhoea method for family planning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28069491" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Shared decision making in contraceptive counseling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24844671" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Divergent practices among Catholic hospitals in provision of direct sterilization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25081864" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Are women aware of religious restrictions on reproductive health at Catholic hospitals? A survey of women's expectations and preferences for family planning care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25081864" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Are women aware of religious restrictions on reproductive health at Catholic hospitals? A survey of women's expectations and preferences for family planning care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30383079" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Balancing the Risks and Desires for Pregnancy in Older Mothers: Increasing Morbidity, Declining Fertility.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26738619" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Racial and ethnic differences in women's preferences for features of contraceptive methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26410174" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Progestogen-only contraceptive use among breastfeeding women: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26002804" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Combined hormonal contraceptive use among breastfeeding women: an updated systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30423320" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Hormonal contraception, breastfeeding and bedside advocacy: the case for patient-centered care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15802407" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Failure to obtain desired postpartum sterilization: risk and predictors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27570140" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Request and fulfillment of postpartum tubal ligation in patients after high-risk pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28578151" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : An updated assessment of postpartum sterilization fulfillment after vaginal delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21843694" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Changing depot medroxyprogesterone acetate access at a faith-based institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15983269" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Sterilized in the name of public health: race, immigration, and reproductive control in modern California.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30568413" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Gendered Power Relations and Informed Consent: The I.V. v. Bolivia Case.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26322647" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Eugenics and Involuntary Sterilization: 1907-2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25808633" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Experiences of coercion to sterilize and forced sterilization among women living with HIV in Latin America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29635207" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Involuntary sterilization among HIV-positive Garifuna women from Honduras seeking asylum in the United States: Two case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24401047" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Medicaid policy on sterilization--anachronistic or still relevant?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29477629" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The use of a low-literacy version of the Medicaid sterilization consent form to assess sterilization-related knowledge in Spanish-speaking women: results from a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28987293" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Society of Family Planning Guidelines: Postplacental insertion of intrauterine devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25397890" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Intrauterine device insertion in the postpartum period: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26115018" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Immediate postpartum insertion of intrauterine device for contraception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14667326" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Analysis of risk factors associated with uterine perforation by intrauterine devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20966692" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Postplacental or delayed insertion of the levonorgestrel intrauterine device after vaginal delivery: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24457061" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Postplacental insertion of the levonorgestrel intrauterine device after cesarean delivery vs. delayed insertion: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25499587" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Intracesarean insertion of the Copper T380A versus 6 weeks postcesarean: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26241250" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Intrauterine Device Placement During Cesarean Delivery and Continued Use 6 Months Postpartum: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22036512" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Puerperal and menstrual bleeding patterns with different types of contraceptive device fitted during elective cesarean delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11368989" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Post-partum bleeding and infection after post-placental IUD insertion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27562797" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Predictors of Non-Attendance to the Postpartum Follow-up Visit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30414598" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Comparing Postpartum Visit Attendance with a Scheduled 2- to 3-Week or 6-Week Visit after Delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30204688" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Intrauterine Device Expulsion After Postpartum Placement: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26475368" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Twelve-month contraceptive continuation and repeat pregnancy among young mothers choosing postdelivery contraceptive implants or postplacental intrauterine devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3907964" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Expulsions in immediate postpartum insertions of Lippes Loop D and Copper T IUDs and their counterpart Delta devices--an epidemiological analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25553871" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A randomized trial of levonorgestrel intrauterine system insertion 6 to 48 h compared to 6 weeks after vaginal delivery; lessons learned.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24499755" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Effects of age, parity, and device type on complications and discontinuation of intrauterine devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25198262" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Association of age and parity with intrauterine device expulsion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31108053" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : A prospective cohort study comparing expulsion after postplacental insertion: the levonorgestrel versus the copper intrauterine device.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32142826" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Expulsion of intrauterine devices after postpartum placement by timing of placement, delivery type, and intrauterine device type: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35226086" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Association of the Timing of Postpartum Intrauterine Device Insertion and Breastfeeding With Risks of Intrauterine Device Expulsion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7081309" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Copper intrauterine contraceptive device event rates following insertion 4 to 8 weeks post partum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36943214" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Early vs Interval Postpartum Intrauterine Device Placement: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35849462" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Ultrasound-Guided Compared With Non-Ultrasound-Guided Placement of Immediate Postpartum Intrauterine Contraceptive Devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29870737" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Six-month expulsion of postplacental copper intrauterine devices placed after vaginal delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34461075" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Complications after interval postpartum intrauterine device insertion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26686914" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Intrauterine device placement at 3 versus 6 weeks postpartum: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33460585" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Design of the Association of Uterine Perforation and Expulsion of Intrauterine Device study: a multisite retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27421765" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The safety of intrauterine devices in breastfeeding women: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28322770" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : IUD use among parous women and risk of uterine perforation: a secondary analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26916172" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: A 7-year randomized comparative study with the TCu380A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22015868" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Malpositioned intrauterine contraceptive devices: risk factors, outcomes, and future pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2257739" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : A randomized trial of the Gyne T 380 and Gyne T 380 Slimline Intrauterine Copper devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11145369" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Comparison of the performances of TCu380A and TCu380S IUDs up to five years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29750926" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Comparative safety and efficacy of a dedicated postpartum IUD inserter versus forceps for immediate postpartum IUD insertion: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29128372" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Six-week retention after postplacental copper intrauterine device placement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27030698" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The effect of depot medroxyprogesterone acetate on postnatal depression: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20654759" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Effect of depot medroxyprogesterone acetate on postpartum depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30741807" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Venous Thromboembolism Among Women Initiating Depot Medroxyprogesterone Acetate Immediately Postpartum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30471261" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Effect of contraceptive choice on rapid repeat pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8154698" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Physiological mechanisms underlying lactational amenorrhea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32685920" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : A novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27467319" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : U.S. Selected Practice Recommendations for Contraceptive Use, 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27467319" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : U.S. Selected Practice Recommendations for Contraceptive Use, 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31436540" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Postpartum hormonal contraception in breastfeeding women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Lactogenesis and breastfeeding after immediate versus delayed birth-hospitalization insertion of etonogestrel contraceptive implant: A non-inferiority trial
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35964661" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Lactogenesis and breastfeeding after immediate vs delayed birth-hospitalization insertion of etonogestrel contraceptive implant: a noninferiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26209863" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Immediate postpartum initiation of etonogestrel-releasing implant: A randomized controlled trial on breastfeeding impact.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30408456" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : The effect of immediate postpartum levonorgestrel contraceptive implant use on breastfeeding and infant growth: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28842126" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Immediate postpartum levonorgestrel intrauterine device insertion and breast-feeding outcomes: a noninferiority randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/780215" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : [Effect of daily oral administration of 0.350 mg of norethindrone on lactation and on the composition of milk].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22143258" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Effect of progestin compared with combined oral contraceptive pills on lactation: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25793657" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Combined hormonal versus nonhormonal versus progestin-only contraception in lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23623474" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Effect of hormonal contraceptives during breastfeeding on infant's milk ingestion and growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21343773" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Risk of venous thromboembolism during the postpartum period: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32459418" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Association of Immediate Postpartum Etonogestrel Implant Insertion and Venous Thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25162263" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20798377" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29496297" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : The relationship between progestin hormonal contraception and depression: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9800931" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
